<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharmacol Sin</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharmacol. Sin</journal-id><journal-id journal-id-type="pmc-domain-id">2405</journal-id><journal-id journal-id-type="pmc-domain">actpharmsin</journal-id><journal-title-group><journal-title>Acta Pharmacologica Sinica</journal-title></journal-title-group><issn pub-type="ppub">1671-4083</issn><issn pub-type="epub">1745-7254</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4011349</article-id><article-id pub-id-type="pmcid-ver">PMC4011349.1</article-id><article-id pub-id-type="pmcaid">4011349</article-id><article-id pub-id-type="pmcaiid">4011349</article-id><article-id pub-id-type="pmid">23064723</article-id><article-id pub-id-type="doi">10.1038/aps.2012.99</article-id><article-id pub-id-type="pii">aps201299</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparative pharmacokinetics of cefuroxime lysine after single intravenous, intraperitoneal, and intramuscular administration to rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="LS">Long-shan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="R">Ran</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="BB">Bin-bin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Q">Qing</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="ZY">Zhen-yuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="XH">Xiao-hui</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bi</surname><given-names initials="KS">Kai-shun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>School of Pharmacy, Shenyang Pharmaceutical University</institution>, Shenyang 110016, <country>China</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail <email>bikaishun@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>15</day><month>10</month><year>2012</year></pub-date><volume>33</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">237316</issue-id><fpage>1348</fpage><lpage>1352</lpage><history><date date-type="received"><day>10</day><month>03</month><year>2012</year></date><date date-type="accepted"><day>04</day><month>06</month><year>2012</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2012</year></date></event><event event-type="pmc-live"><date><day>19</day><month>09</month><year>2014</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-25 00:25:09.323"><day>25</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2012 CPS and SIMM</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>CPS and SIMM</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="aps201299a.pdf"/><abstract><sec><title>Aim:</title><p>To compare the pharmacokinetic parameters of cefuroxime lysine, a new second-generation of cephalosporin antibiotics, after intravenous (IV), intraperitoneal (IP), or intramuscular (IM) administration.</p></sec><sec><title>Methods:</title><p>Twelve male and 12 virgin female Sprague-Dawley rats, weighing from 200 to 250 g, were divided into three groups (<italic toggle="yes">n</italic>=4 for each gender in each group). The rats were administered a single dose (67.5 mg/kg) of cefuroxime lysine via IV bolus or IP or IM injection. Blood samples were collected and analyzed with a validated UFLC-MS/MS method. The concentration-time data were then calculated by compartmental and non-compartmental pharmacokinetic methods using DAS software.</p></sec><sec><title>Results:</title><p>After IV, IP or IM administration, the plasma cefuroxime lysine disposition was best described by a tri-compartmental, bi-compartmental or mono-compartmental open model, respectively, with first-order elimination. The plasma concentration profiles were similar through the 3 administration routes. The distribution process was rapid after IV administration [<italic toggle="yes">t</italic><sub>1/2(d)</sub>, 0.10&#177;0.11 h <italic toggle="yes">vs</italic> 1.36&#177;0.65 and 1.25&#177;1.01 h]. The AUMC<sub>0&#8211;&#8734;</sub> is markedly larger, and mean residence time (MRT) is greatly longer after IP administration than that in IV, or IM routes (AUMC<sub>0&#8211;&#8734;</sub>: 55.33&#177;20.34 <italic toggle="yes">vs</italic> 16.84&#177;4.85 and 36.17&#177;13.24 mg&#183;h<sup>2</sup>/L; MRT: 0.93&#177;0.10 h <italic toggle="yes">vs</italic> 0.37&#177;0.07 h and 0.65&#177;0.05 h). The <italic toggle="yes">C</italic><sub>max</sub> after IM injection was significantly higher than that in IP injection (73.51&#177;12.46 <italic toggle="yes">vs</italic> 49.09&#177;7.06 mg/L). The AUC<sub>0&#8211;&#8734;</sub> in male rats were significantly higher than that in female rats after IM administration (66.38&#177;16.5 <italic toggle="yes">vs</italic> 44.23&#177;6.37 mg&#183;h/L). There was no significantly sex-related difference in other pharmacokinetic parameters of cefuroxime lysine between male and female rats.</p></sec><sec><title>Conclusion:</title><p>Cefuroxime lysine shows quick absorption after IV injection, a long retension after IP injection, and a high <italic toggle="yes">C</italic><sub>max</sub> after IM injection. After IM administration the AUC<sub>0&#8211;&#8734;</sub> in male rats was significantly larger than that in female rats.</p></sec></abstract><kwd-group><kwd>cefuroxime lysine</kwd><kwd>intravenous administration</kwd><kwd>intramuscular administration</kwd><kwd>intraperitoneal administration</kwd><kwd>pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>